Literature DB >> 3106094

Prolactin response to thyrotropin-releasing hormone in women with infertility and/or randomly elevated serum prolactin levels.

D F Archer.   

Abstract

Infertile women with normal serum prolactin (PRL) levels have been known to establish a pregnancy after the use of bromocriptine, a dopamine agonist. These data imply that there may be a group of women with a slight but significant increase in PRL secretion that may have resulted in their infertility. This study evaluates the thyrotropin-releasing hormone (TRH)-induced PRL and thyroid-stimulating hormone (TSH) response in normal women (NL, n = 6), women with anovulation and/or inphase endometrial biopsies (AN/IN, n = 12), and women with histologic evidence of luteal phase deficiency (LPD, n = 12). Most of these women were found to have elevated serum PRL values on random testing. There was a statistically significant increase in PRL response at all time intervals after TRH between the NL and AN/IN groups compared with the group with LPD on the basis of repeated measures analysis (P = 0.0013). There was no statistical difference in the TSH response between these three groups. Although the PRL response was statistically different, individual PRL response patterns were not diagnostic. It appears from these data that there is an increased PRL secretion in infertile women who have histological evidence of a LPD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106094     DOI: 10.1016/s0015-0282(16)59102-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  1 in total

Review 1.  The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology.

Authors:  Renata S Auriemma; Guendalina Del Vecchio; Roberta Scairati; Rosa Pirchio; Alessia Liccardi; Nunzia Verde; Cristina de Angelis; Davide Menafra; Claudia Pivonello; Alessandro Conforti; Carlo Alviggi; Rosario Pivonello; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-09       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.